Oral propranolol combined with topical timolol for compound infantile hemangiomas: a retrospective study.
Oral propranolol combined with topical timolol for compound infantile hemangiomas: a retrospective study.
复制标题
口服普萘洛尔联合外用噻吗洛尔治疗婴儿复合血管瘤的回顾性研究
DOI：
10.1038/srep19765
复制
发表时间：
2016-01-28
影响因子：
4.6
通讯作者：
Zhao H
中科院分区：
文献类型：
--
作者：
Ge J;Zheng J;Zhang L;Yuan W;Zhao H
复合婴儿血管瘤（IHs）是有问题的，通常需要干预。本回顾性研究旨在介绍口服心得安与外用替马洛尔联合治疗，并评价其疗效和安全性。89例患有复合IHs的婴儿口服心得安2mg /kg/天，每天2次，口服0.5%马来酸替莫洛尔凝胶每天3次，治疗至少3个月。两名观察员分别在治疗开始后0、1、3、6、9个月独立评估血管瘤。使用配对t检验评估血管瘤评分值的变化。记录反弹生长和不良反应。治疗完成后，这种联合治疗在100%的患者中获得了临床反应（89/89）。治疗后1、3、6个月疗效显著（p < 0.001）， 6个月后不明显（p = 0.06）。IHs对治疗的反应取决于初始治疗时的年龄。平均治疗时间为6.48（5.77 ~ 7.19）个月。停止治疗6个月后复发1例（1.1%），出现不良反应7例（7.8%）。本研究提示口服心得安联合局部替洛尔治疗复合IHs疗效显著，耐受性良好，可作为一线治疗。
Compound infantile hemangiomas (IHs) are problematic and usually require intervention. This retrospective study aimed to introduce a combined therapy of oral propranolol and topical timolol and evaluate its efficacy and safety. Eighty-nine infants with compound IHs were treated with oral propranolol 2 mg/kg/day divided 2 times per day and timolol maleate 0.5% gel 3 times per day, for at least 3 months. Two observers evaluated the hemangioma independently at 0, 1, 3, 6, 9 months after the initiation of treatment. Changes in the hemangioma score values were evaluated using paired t test. Rebound growth and adverse effects were recorded. After treatment was completed, this combined therapy achieved clinical response in 100% of the patients (89/89). Significant positive effects were demonstrated at 1, 3, 6 months (p < 0.001), but not obvious after 6 months (p = 0.06). The response of IHs to the therapy was depending on the age at initial treatment. The average treatment duration was 6.48 (5.77–7.19) months. One patient (1.1%) relapsed after cessation of 6-month treatment and 7 children (7.8%) developed side effects. Our study suggested that oral propranolol combined with topical timolol treatment is very effective and well-tolerated for compound IHs, which can be used as a first line treatment.